ABSCF (AB Science) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABSCF AB Science ABSCF
60 GF Score
Price $1.12
GF Value $1.39
Valuation Modestly Undervalued
! 11 Warning Signs
View Full Analysis

What is AB Science Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

ABSCF
60GF Score
AB Science ABSCF
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AB Science (ABSCF) Overvalued in 2026?

Based on GuruFocus' analysis, AB Science stock appears to be undervalued. The current stock price of $1.12 is trading 19.4% below its estimated GF Value™ of $1.39. GuruFocus considers AB Science to be Modestly Undervalued.

Key valuation signals for ABSCF:

  • Dividends Received:
  • GF Value™: $1.39 vs. price of $1.12 (19.4% below fair value)
  • GF Score™: 60/100 with 11 warning signs

No single metric tells the full story. See the ABSCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AB Science Business Description

Other Exchanges 0Q77:UKAB:FranceA8D:Germany
Address 3, Avenue George V, Paris, FRA, 75008
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
60GF Score

Get the complete analysis for ABSCF

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.12
Price
$1.39
GF Value